Generic semaglutide is now real in Canada, but it isn't available for sale as a U.S. generic. Health Canada authorized its first version for type 2 diabetes in April 2026 and its first for chronic weight management in June. In the United States, one application has tentative approval, which does not permit marketing. Compounded semaglutide is not the missing generic; it is a patient-specific pharmacy preparation under a different set of rules.
What changed for generic semaglutide in 2026
On April 28, Health Canada authorized a semaglutide injection from Dr. Reddy's Laboratories as a generic of Ozempic. It was the first generic semaglutide authorized in a G7 country, and its indication was type 2 diabetes—not weight management (Health Canada, April 28, 2026).
The story moved again on June 29. Health Canada authorized Sevmia, made by Apotex, as the first Canadian generic of Wegovy for chronic weight management. The agency called it the country's third authorized semaglutide generic and said it had reviewed the product for safety, effectiveness, and quality under its generic-drug standards (Health Canada, June 29, 2026).
As of September 9, 2026, the day this article was written, those Canadian authorizations had not created a generic semaglutide product that could be sold in the United States. Drug approvals and patent rights stop at national borders. A Canadian authorization answers what can be marketed in Canada.
Why the U.S. still has no marketed generic
Apotex announced on April 10, 2026 that FDA had granted tentative approval to its abbreviated new drug application, or ANDA—the U.S. application route for a generic semaglutide injection. Tentative approval means the application is not yet eligible for final approval and the product cannot be marketed. Apotex itself said the product still had to become eligible for final approval (Apotex, April 10, 2026).
Patents are the other part of the wait. FDA's July 2026 Orange Book—the agency's record of approved drugs and listed patents—shows patent 8,129,343, which covers the semaglutide molecule, expiring December 5, 2031, with several product and use patents lasting longer (FDA Orange Book, July 2026). Novo Nordisk's 2025 annual filing puts the U.S. expiry of the patent covering that molecule at 2032 for Ozempic, Rybelsus, and Wegovy (SEC filing).
That makes late 2031 into 2032 the clearest early window people are talking about. It isn't a promised launch date. Patent challenges, confidential settlements, final FDA review, manufacturing readiness, and the particular brand formulation can all change when a product actually reaches pharmacies.
Compounded semaglutide is not a generic
A compounded preparation is not a generic: a generic must receive its own FDA approval and meet the agency's standards for sameness to a reference product. FDA says a generic is comparable in dosage form, strength, route, quality, performance, and intended use; the applicant must demonstrate bioequivalence, meaning it delivers the active ingredient into the bloodstream at a comparable rate and amount (FDA's ANDA explanation).
Compounding follows a separate framework. A compounding pharmacy prepares medication for an identified patient under a prescription. In its 2026 guidance to telehealth companies, FDA says describing a compounded drug as a generic is misleading because the compounded preparation does not receive FDA premarket review for safety, effectiveness, or quality (FDA telehealth guidance).
Through Promise, semaglutide is dispensed as a compounded medication, which is different from an FDA-approved product: the formulation offered here is not FDA-approved. The fuller compounded semaglutide explainer covers the patient-specific rules and pharmacy label in detail.
| Question | U.S. generic | Compounded prescription |
|---|---|---|
| Regulatory route | Final ANDA approval | Federal and state compounding rules |
| Product standard | Must match a reference drug on required features | Prepared for an identified patient |
| Premarket FDA review | Yes, for the generic product | No, for the individual preparation |
| Market status today | Tentative approval only; not for sale | May be prescribed when applicable conditions are met |
The distinction isn't just paperwork. A 2025 laboratory study found that pH, buffer strength, and temperature changed semaglutide's stability (Malgave et al., Journal of Peptide Science). In a 2026 randomized trial of 314 adults in India, a new semaglutide injection was directly compared with reference semaglutide for 24 weeks; it met the study's preset bar for blood-sugar control and had similar side-effect rates (Sharma et al., Metabolism Open). HbA1c, the trial's main measure, estimates average blood sugar over roughly three months.
Those studies do not evaluate Promise's compounded preparation. They show why the finished formulation and the evidence attached to it matter, even when the molecule's name is the same.
What the U.S. choices actually are now
For semaglutide, the available paths are a branded product such as Ozempic or Wegovy through insurance, a retail pharmacy, or a manufacturer program; or, when a prescriber documents a patient-specific reason and the legal conditions are met, a compounded prescription. The current semaglutide cost guide compares those routes without pretending they are interchangeable.
Tirzepatide is sometimes presented as though it were a generic substitute. It isn't. It is a different molecule with its own prescription decision, evidence, side effects, brands, and compounding rules. The direct-brand-versus-compounding comparison shows how those fulfillment routes differ without treating one drug as a copy of the other.
Can a U.S. patient import the Canadian generic?
Usually not. FDA says that in most circumstances an individual may not import a foreign drug for personal use when that finished product has not been approved for U.S. sale. The agency describes narrow situations in which staff may exercise discretion, generally involving a serious condition with no effective domestic treatment, no U.S. promotion, no unreasonable risk, a small personal-use quantity, and supporting medical information (FDA personal-importation policy).
That discretion is not a personal importation right or a dependable mail-order pathway. The existence of Canadian generic semaglutide does not turn a cross-border pharmacy listing into a lawful U.S. prescription option.
What to check before choosing a route
The useful questions are concrete: What exact finished product will be dispensed? Who wrote the prescription? Which licensed U.S. pharmacy is on the label? What concentration and instructions apply to that container? Who handles side effects or a refill problem? Those answers tell you far more than the word “generic” on an advertisement.
A licensed provider may still prescribe a compounded formulation when the legal and clinical conditions are met; that decision is between the patient and the doctor. At Promise, a licensed provider reviews every request, and not everyone qualifies.